ReviewJournal of personalized medicine2018
Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis.
Review in Journal of personalized medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- SMART Planning of Early-Stage Health Economic Decision Models for Mechanism-Based Precision Treatments in Rare Cancers: An Application and Tool Update.PharmacoEconomics · 2026Review
- Implementing health economics for pharmacogenomics research translation in Africa.Communications medicine · 2025Review
- Delineating mouse β-cell identity during lifetime and in diabetes with a single cell atlas.Nature metabolism · 2023Article
- Recognizing the ethical implications of stem cell research: A call for broadening the scope.Stem cell reports · 2021Review
- Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective.ClinicoEconomics and outcomes research : CEOR · 2021Article
- The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement.Current therapeutic research, clinical and experimental · 2021Review
- Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.Computational and structural biotechnology journal · 2020Article
- Immunogenicity of Tumor Initiating Stem Cells: Potential Applications in Novel Anticancer Therapy.Frontiers in oncology · 2019Review
- Repositioning Drugs for Psychiatry.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The pricing of targeted medicines continues to be a major area of contention in healthcare economics. This issue is further complicated by redefining the role of molecular testing in precision medicine. Currently, whilst pricing of clinical laboratory diagnostics is cost-based, drug pricing is value-based. The pricing for molecular testing is under pressure to change the traditional business model, for it has a critical subsidiary role in determining the final value of targeted medicines. The market size for drugs is reduced by molecular testing when patients with the same disease are stratified based on their genetics, it is critical to determine the value of this new enhanced drug specificity to realize its full pricing potential. However, these value-based pricing strategies require a careful understanding of changing market conditions, especially, in the context of stratified patient segments made possible by precision medicine. In this article, we discuss the various factors impacting pricing decisions, and consider evolving economic trends in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.